文献速递肾小球疾病

利妥昔单抗后外周血B细胞清除与狼疮性肾炎完全缓解的关系

Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis.
PubMed 文献 · Clin J Am Soc Nephrol · 2018-08-08

该研究基于LUNAR试验数据,分析68例接受利妥昔单抗治疗的狼疮性肾炎患者,评估外周血B细胞完全清除(0细胞/µl)与第78周完全缓解的关联。结果显示78%患者实现完全清除,中位时间182天,完全清除者完全缓解率更高(47% vs 13%),且清除速度与持续时间均与缓解相关。

要点

  • 利妥昔单抗治疗后外周血B细胞完全清除与狼疮性肾炎完全缓解独立相关。
  • 完全清除实现时间越晚,完全缓解可能性越低。
  • 完全清除持续时间超过中位数71天者更易达到完全缓解。

核心结论

  • 利妥昔单抗治疗后外周血B细胞完全清除、清除速度及持续时间均与第78周完全缓解相关。

研究设计与样本

  • 基于LUNAR试验数据,分析68例接受利妥昔单抗治疗的狼疮性肾炎患者,随访78周。

主要发现

  • 53例(78%)实现完全外周血B细胞清除(0细胞/µl),中位时间182天(IQR 80-339)。
  • 完全清除中位持续时间71天(IQR 14-158)。
  • 完全清除与完全缓解相关(未校正OR 5.8,95%CI 1.2-28,P=0.03)。
  • 实现完全清除时间越长,完全缓解可能性越低(未校正OR 0.89,95%CI 0.81-0.98,P=0.02);完全清除持续>71天与完全缓解相关(未校正OR 4.1,95%CI 1.5-11,P=0.008)。

关键数值与推荐

  • 完全外周血B细胞清除定义为0细胞/µl。
  • 完全缓解定义为尿蛋白/肌酐比值<0.5 mg/mg,且血肌酐正常或较基线(若基线正常)升高<15%。

临床怎么用

  • 监测利妥昔单抗治疗后外周血B细胞清除情况可能有助于预测狼疮性肾炎的缓解概率。
  • 实现完全清除的速度和持续时间可作为评估治疗反应的参考指标。

局限性

  • 研究为基于LUNAR试验数据的回顾性分析,样本量有限(68例)。
  • associations为未校正分析,可能存在混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Incomplete peripheral blood B cell depletion after rituximab in lupus nephritis might correlate with inability to reduce tubulointerstitial lymphoid aggregates in the kidney, which together could be responsible for inadequate response to treatment. We utilized data from the Lupus Nephritis Assessment with Rituximab (LUNAR) study to characterize the variability of peripheral blood B cell depletion after rituximab and assess its association with complete response in patients with lupus nephritis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We analyzed 68 participants treated with rituximab. Peripheral blood B cell depletion was defined as 0 cells/µl, termed "complete peripheral depletion," assessed over 78 weeks. Logistic regression was used to estimate the association between characteristics of complete peripheral depletion and complete response (defined as urine protein-to-creatinine ratio <0.5 mg/mg, and normal serum creatinine or an increase in creatinine <15%, if normal at baseline), assessed at week 78. RESULTS: A total of 53 (78%) participants achieved complete peripheral depletion (0 cells/µl) in a median time of 182 days (interquartile range, 80-339).The median duration of complete peripheral depletion was 71 days (interquartile range, 14-158). Twenty-five (47%) participants with complete peripheral depletion achieved complete response, compared with two (13%) without. Complete peripheral depletion was associated with complete response (unadjusted odds ratio [OR], 5.8; 95% confidence interval [95% CI], 1.2 to 28; P=0.03). Longer time to achieving complete peripheral depletion was associated with a lower likelihood of complete response (unadjusted OR, 0.89; 95% CI, 0.81 to 0.98; P=0.02). Complete peripheral depletion lasting >71 days (the median) was associated with complete response (unadjusted OR, 4.1; 95% CI, 1.5 to 11; P=0.008). CONCLUSIONS: There was substantial variability in peripheral blood B cell depletion in patients with lupus nephritis treated with rituximab from the LUNAR trial. Achievement of complete peripheral depletion, as well as the rapidity and duration of complete peripheral depletion, were associated with complete response at week 78. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_09_06_CJASNPodcast_18_10_.mp3.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Gomez Mendez LM, Cascino MD, Garg J, et al. Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis. Clin J Am Soc Nephrol. 2018. PMID: 30089664. doi:10.2215/CJN.01070118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。